M.D. Anderson Cancer Center
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Primary Objectives * To determine differences in PFS based on differential response markers in paired tissue biopsies (Part I). * To improve progression-free survival with novel intervention strategies (Part II) Secondary Objectives * To collect serial tissue and blood biomarkers and efficacy data associated with standard of care or investigational therapy across multiple lines of therapy. * To determine the overall response rate (ORR), and overall survival (OS) based on the presence of specific biomarkers or adaptive interventions.
Eligibility Criteria * The participant has a histologically or cytologically confirmed diagnosis of colorectal cancer. * Confirmation of non-MSI-H/pMMR status. * Tumor that is measurable as per RECIST v1.1 and biopsy able, defined as lesion/tumor that can be biopsied without undue risk. * Age ≥ 18 years. * ECOG performance status 0-2. * Due to the potential teratogenic effect of chemotherapy, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for…
Blood draws, biopsies, samples and MRI.
Given by IV
Given by Iv
Given by Iv
Given by Iv
Given by Iv
Given by po
Given by Po
Given by po
Given by IV
Given by po
Given by po
Arctuva estimate
Verify or correct the compensation shown for this listing.